Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Therapeutics and Clinical Risk Management|July 8, 2015
A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemiaDavid L Tucker, Simon A Rule
Future Oncology (London, England)|January 14, 2016
Ibrutinib for mantle cell lymphomaDavid L Tucker, Simon A Rule
British Journal of Haematology|February 4, 2020
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapyRory McCulloch, Carlo Visco, Toby A Eyre, et al.
Blood Advances|September 3, 2025
Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCLJon E Arnason, Matthew J Matasar, Stefano Luminari, et al.
Military Medicine|April 6, 2016
Economic Burden of Hearing Loss for the U.S. Military: A Proposed Framework for EstimationHasanat Alamgir, David L Tucker, Sun-Young Kim, et al.
Military Medicine|December 4, 2014
The Department of Defense Epidemiologic and Economic Burden of Hearing Loss studySharon P Cooper, Hasanat Alamgir, Kristina W Whitworth, et al.
Blood Advances|April 29, 2026
Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC studyToby A Eyre, Nicolás Martínez-Calle, Shankara Paneesha, et al.
Pageof 1